DEPARTMENT OF HEALTH AND HUMAN SERVICES

Display Date 8-5-02
Publication Date 8-6-02
Certifier 8. LEDESMA

Food and Drug Administration

21 CFR Part 510

New Animal Drugs; Change of Sponsor's Address

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

書

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor's address for Endo Pharmaceuticals, Inc.

DATES: This rule is effective [insert date of publication in the Federal Register].

FOR FURTHER INFORMATION CONTACT: Lonnie W. Luther, Center for Veterinary Medicine (HFV–101), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–0209, e-mail: lluther@cvm.fda.gov.

SUPPLEMENTARY INFORMATION: Endo Pharmaceuticals, Inc., 223 Wilmington West Chester Pike, Chadds Ford, PA 19317, has informed FDA of a change of sponsor address to 100 Painters Dr., Chadds Ford, PA 19317. Accordingly, the agency is amending the regulations in 21 CFR 510.600(c)(1) and (c)(2) to reflect the change of sponsor address.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 510

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

cv0219

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 510 is amended as follows:

PART 510—NEW ANIMAL DRUGS

1. The authority citation for 21 CFR part 510 continues to read as follows:

Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

2. Section 510.600 is amended in the table in paragraph (c)(1) by revising the entry for "Endo Pharmaceuticals, Inc." and in the table in paragraph (c)(2) by revising the entry for "060951" to read as follows:

§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.

(c) * * *

(1)***

| | Firm name and address | Drug labeler code |
|--|--|---|
| | | |
| o Pharmaceuticals, Inc., 100 | Painters Dr., Chadds Ford, PA 19317 | aati alkalikusta on akulkalisi kii uuskaa kii purantamuun suuratiisissoonitiin vuotiin kulka eesta kulkalisissa kalkalikusi kanka kankaa kiiska |
| The second secon | | |
| | | |
| (2) * * * | | |
| (4) | Property and the second of the | editain kulka tihak putan niikuusissa saksun saksumakanka saksun essassi maan asis sa saksi saksa siib su niik |
| Drug labeler code | Firm name and addre | 966 |
| | | |
| 951 | Endo Pharmaceuticals, Inc., 100 Painters Dr. | |

Dated: July 19, 2002.

Andrew J. Beaulieu,

Acting Director,

Office of New Animal Drug Evaluation,

Center for Veterinary Medicine.

[FR Doc. 02-????? Filed ??-??-02; 8:45 am]

BILLING CODE 4160-01-S

CERTIFIED TO BE A TRUE COPY OF THE ORIGINAL

Byin Sedem